{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:27:05Z","timestamp":1793813225590,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 2020 ID 24698"],"award-info":[{"award-number":["MFAG 2020 ID 24698"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.annonc.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:20:49Z","timestamp":1789662049000},"page":"1453-1456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"L.","family":"Arecco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.annonc.2026.09.006_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.006_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.09.006_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.006_bib4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.annonc.2026.08.002","article-title":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-\/- associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","volume":"37","author":"Garber","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.09.006_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104820","article-title":"Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials","volume":"88","author":"Buonaiuto","year":"2026","journal-title":"Breast"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.006_bib6","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.09.006_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2021.06.032","article-title":"OncotypeDX\u00a9 Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis","volume":"154","author":"Davey","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.006_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","article-title":"Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers","volume":"35","author":"Arecco","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.006_bib9","article-title":"Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer [abstract]","volume":"43","author":"Yadav","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8110","key":"10.1016\/j.annonc.2026.09.006_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41586-026-10197-0","article-title":"Homologous recombination deficiency and hemizygosity drive resistance in breast cancer","volume":"652","author":"Safonov","year":"2026","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.006_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41698-026-01481-3","article-title":"Germline BRCA2 mutations foster resistance to CDK4\/6 inhibitors in breast cancer","volume":"10","author":"Bolini","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.annonc.2026.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104544","article-title":"Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2- metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis","volume":"83","author":"Bottosso","year":"2025","journal-title":"Breast"},{"issue":"12 suppl","key":"10.1016\/j.annonc.2026.09.006_bib13","first-page":"P2-10","volume":"31","author":"Razavi","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.annonc.2026.09.006_bib14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.09.006_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors","volume":"10","author":"Vikas","year":"2020","journal-title":"Front Oncol"},{"issue":"4 suppl","key":"10.1016\/j.annonc.2026.09.006_bib16","article-title":"Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer","volume":"32","author":"Tung","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"4 suppl","key":"10.1016\/j.annonc.2026.09.006_bib17","article-title":"Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts","volume":"32","author":"Mayer","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.006_bib18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.09.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112944","article-title":"Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments","volume":"190","author":"Valenza","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.006_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.006_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.09.006_bib22","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/humrep\/deaf096","article-title":"Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies","volume":"40","author":"Arecco","year":"2025","journal-title":"Hum Reprod"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.006_bib23","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/humrep\/deaa128","article-title":"The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","volume":"35","author":"Winship","year":"2020","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.006_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2023.25463","article-title":"Pregnancy after breast cancer in young BRCA carriers: an international hospital-based cohort study","volume":"331","author":"Lambertini","year":"2024","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.006_bib25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:31:00Z","timestamp":1793809860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0923753426066494"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.08.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}